Company Performance Metrics
GC Green Cross Their goal is to contribute to the healthy life of mankind and become a global leader in the healthcare industry. Recent advances in biotechnology have become a good foundation for achieving their goals.
The paradigm of medicine is changing. They are shifting from traditional medicines and synthetic medicines to biopharmaceutical
development. GC Green Cross Cellular gene therapy, which is the main pipeline of LAPSEL, is expected to enable the treatment of rare and intractable diseases as well as cancer, because of the fundamental treatment of diseases at the gene and cell level.
In particular, successful cases such as approval of the first immunotherapeutic drug (CAR-T) in 2017 and the approval of the first gene therapy (Luxturna) were epoch-making events that transformed the expectations they had in mind into reality. Is added.
